Literature DB >> 17899225

[Survival improvement of a unicentric overall population in 20 years: 1038 patients with oral and oropharyngeal squamous cell cancer 1983-2004].

Adorján F Kovács1, Waleed Megahed, Michael Scholz, Robert Sader.   

Abstract

PURPOSE: The development of overall survival of a DOSAK (German-Austrian-Swiss Cooperative Group on tumours of the maxillofacial region) clinic's overall population comprising a time period of more than 20 years (1983-2004) should be assessed. At a cutoff date (January 1st, 1997), a change from a primarily surgically based to a consequent multi-modality treatment regimen was implemented. The periods of time before and after that change should be compared. METHODS AND PATIENTS: The data of the DOSAK registry entries on 1038 patients suffering from primary untreated oral and oropharyngeal carcinomas were updated with respect to follow-up and mortality data to achieve a 100% quality of follow-up. The end point (death) was reached in 67% of the overall population. Statistical analysis was carried out by the Trium Analysis Online corporation, Munich.
RESULTS: The portion of female and older tumor patients increased, more than half of all tumor patients were clearly in stage IV of the disease at first referral. The portion of patients operated on persisted approximately (80%), the portion of additional treatment modalities could be increased considerably. The fact of a bony infiltration by the tumor and the operability remained highly significantly relevant for survival in multivariate analysis, despite of multi-modality treatment. The survival rate of the patients remained significantly dependent on the clinical stage of the disease in multivariate analysis but could be improved by 10% in the clinical stages II and III and in the patients who could not be operated on. All in all, the cutoff date was statistically relevant for survival in multivariate analysis, i.[Symbol: see text]e. the change in the treatment regimen had a verifiable positive effect on the survival of a unicentric overall population.
CONCLUSION: Survival improvement in an overall population via change in treatment strategy is possible in relatively short time; the clinical stages II and III and the non-operable patients have the greatest benefit from a multi-modality treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17899225     DOI: 10.1007/s10006-007-0077-1

Source DB:  PubMed          Journal:  Mund Kiefer Gesichtschir        ISSN: 1432-9417


  11 in total

1.  The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins.

Authors:  Dinesh K Badakh; Amit H Grover
Journal:  Indian J Cancer       Date:  2005 Jan-Mar       Impact factor: 1.224

2.  Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge.

Authors:  S Silverman
Journal:  J Am Dent Assoc       Date:  2001-11       Impact factor: 3.634

Review 3.  American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer.

Authors:  David G Pfister; Scott A Laurie; Gregory S Weinstein; William M Mendenhall; David J Adelstein; K Kian Ang; Gary L Clayman; Susan G Fisher; Arlene A Forastiere; Louis B Harrison; Jean-Louis Lefebvre; Nancy Leupold; Marcy A List; Bernard O O'Malley; Snehal Patel; Marshall R Posner; Michael A Schwartz; Gregory T Wolf
Journal:  J Clin Oncol       Date:  2006-07-10       Impact factor: 44.544

4.  Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.

Authors:  Adorján F Kovács; Stephan Mose; Heinz D Böttcher; Klaus Bitter
Journal:  Strahlenther Onkol       Date:  2005-01       Impact factor: 3.621

5.  Maximized combined modality treatment of an unselected population of oral and oropharyngeal cancer patients. Final results of a pilot study compared with a treatment-dependent prognosis index.

Authors:  Adorján F Kovács
Journal:  J Craniomaxillofac Surg       Date:  2006-01-19       Impact factor: 2.078

6.  [Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations].

Authors:  A F Kovács; K Eberlein; A Smolarz; S Weidauer; S Rohde
Journal:  Mund Kiefer Gesichtschir       Date:  2006-05

7.  Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report.

Authors:  Gerry F Funk; Lucy Hynds Karnell; Robert A Robinson; Weining K Zhen; Douglas K Trask; Henry T Hoffman
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

8.  Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients.

Authors:  C Klug; A Wutzl; C Kermer; M Voracek; G Kornek; E Selzer; C Glaser; P W Poeschl; W Millesi; R Ewers
Journal:  Int J Oral Maxillofac Surg       Date:  2005-03       Impact factor: 2.789

9.  Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.

Authors:  A F Kovács; M T Ghahremani; U Stefenelli; K Bitter
Journal:  J Chemother       Date:  2003-10       Impact factor: 1.714

10.  Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.

Authors:  Adorján F Kovács; Mirko Schiemann; Bernd Turowski
Journal:  J Craniomaxillofac Surg       Date:  2002-04       Impact factor: 2.078

View more
  1 in total

1.  Influence of Educational Level, Stage, and Histological Type on Survival of Oral Cancer in a Brazilian Population: A Retrospective Study of 10 Years Observation.

Authors:  Thinali Sousa Dantas; Paulo Goberlânio de Barros Silva; Eric Fernandes Sousa; Maria do Pss da Cunha; Andréa Silvia Walter de Aguiar; Fábio Wildson Gurgel Costa; Mário Rogério Lima Mota; Ana Paula Negreiros Nunes Alves; Fabrício Bitu Sousa
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.